SurModics Company Insiders
| SRDX Stock | USD 36.88 0.24 0.66% |
SurModics employs about 10 people. The company is managed by 10 executives with a total tenure of roughly 58 years, averaging almost 5.0 years of service per executive, having 1.0 employees per reported executive. Break down of SurModics' management performance can provide insight into the company performance.
| Gary Maharaj CEO CEO and President and Director |
| Gregg Sutton President Vice President - Research & Development |
SurModics |
SurModics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with SurModics' future performance. Based on our forecasts, it is anticipated that SurModics will maintain a workforce of slightly above 120 employees by February 2025.SurModics Management Team Effectiveness
Return On Tangible Assets is likely to rise to -0.11 in 2025. Return On Capital Employed is likely to rise to -0.04 in 2025. At this time, SurModics' Other Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 60.7 M in 2025, whereas Total Assets are likely to drop slightly above 142.8 M in 2025. SurModics' management efficiency ratios could be used to measure how well SurModics manages its routine affairs as well as how well it operates its assets and liabilities.Common Stock Shares Outstanding is likely to rise to about 13.6 M in 2025, despite the fact that Net Loss is likely to grow to (23.3 M).
SurModics Workforce Comparison
SurModics is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 26,055. SurModics adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
SurModics Profit Margins
The company has Profit Margin (PM) of (0.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.02) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.02.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.78 | 0.85 |
|
|
SurModics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific SurModics insiders, such as employees or executives, is commonly permitted as long as it does not rely on SurModics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, SurModics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-09-01 | 0.5 | 4 | 8 | 119,196 | 222,655 |
| 2024-03-01 | 2.1667 | 13 | 6 | 40,519 | 20,586 |
| 2023-12-01 | 0.6667 | 18 | 27 | 310,031 | 81,583 |
| 2022-12-01 | 0.6923 | 18 | 26 | 273,244 | 38,756 |
| 2022-09-01 | 0.6667 | 2 | 3 | 20,514 | 55,240 |
| 2022-06-01 | 0.25 | 1 | 4 | 480.00 | 4,490 |
| 2022-03-01 | 3.0 | 12 | 4 | 29,796 | 11,994 |
| 2021-12-01 | 0.6897 | 20 | 29 | 228,784 | 48,023 |
| 2021-09-01 | 0.4 | 6 | 15 | 34,470 | 67,554 |
| 2021-06-01 | 0.3333 | 2 | 6 | 674.00 | 6,082 |
| 2021-03-01 | 0.84 | 21 | 25 | 137,567 | 217,360 |
| 2020-12-01 | 0.9545 | 21 | 22 | 236,137 | 29,526 |
| 2020-09-01 | 0.3333 | 3 | 9 | 13,488 | 33,956 |
| 2020-06-01 | 1.2 | 6 | 5 | 25,809 | 3,552 |
| 2020-03-01 | 8.0 | 16 | 2 | 53,027 | 2,523 |
| 2019-12-01 | 0.8158 | 31 | 38 | 284,857 | 66,966 |
| 2019-09-01 | 0.1818 | 2 | 11 | 639.00 | 21,172 |
| 2019-06-01 | 1.0 | 4 | 4 | 4,166 | 15,131 |
| 2019-03-01 | 1.0769 | 14 | 13 | 22,824 | 14,402 |
| 2018-12-01 | 0.9 | 27 | 30 | 233,203 | 56,564 |
| 2018-09-01 | 0.6 | 15 | 25 | 47,093 | 97,715 |
| 2018-06-01 | 0.4643 | 13 | 28 | 138,516 | 295,281 |
| 2018-03-01 | 1.4118 | 24 | 17 | 202,604 | 277,849 |
| 2017-12-01 | 1.7143 | 24 | 14 | 315,353 | 29,575 |
| 2017-09-01 | 0.75 | 3 | 4 | 9,324 | 11,801 |
| 2017-06-01 | 0.75 | 3 | 4 | 5,832 | 5,512 |
| 2017-03-01 | 5.5 | 11 | 2 | 26,450 | 6,000 |
| 2016-12-01 | 1.7333 | 26 | 15 | 231,191 | 37,867 |
| 2016-09-01 | 0.5 | 17 | 34 | 294,237 | 508,529 |
| 2016-06-01 | 0.7143 | 5 | 7 | 18,662 | 29,670 |
| 2016-03-01 | 1.6667 | 5 | 3 | 23,758 | 11,969 |
| 2015-12-01 | 4.0 | 28 | 7 | 253,322 | 15,269 |
| 2015-09-01 | 1.0 | 3 | 3 | 1,658 | 11,000 |
| 2015-06-01 | 1.1667 | 7 | 6 | 18,246 | 41,054 |
| 2015-03-01 | 1.0 | 5 | 5 | 24,356 | 36,065 |
| 2014-12-01 | 2.8182 | 31 | 11 | 275,594 | 59,826 |
| 2014-09-01 | 3.0 | 3 | 1 | 1,891 | 1,000.00 |
| 2014-06-01 | 1.2 | 6 | 5 | 18,103 | 30,530 |
| 2014-03-01 | 2.25 | 9 | 4 | 23,805 | 10,810 |
| 2013-12-01 | 4.2222 | 38 | 9 | 303,057 | 113,297 |
| 2013-06-01 | 2.0 | 6 | 3 | 3,996 | 3,386 |
| 2013-03-01 | 3.0 | 6 | 2 | 30,722 | 1,650 |
| 2011-12-01 | 15.0 | 15 | 1 | 253,810 | 1,635 |
| 2010-12-01 | 3.0 | 21 | 7 | 481,950 | 11,200 |
| 2010-09-01 | 0.3333 | 1 | 3 | 14,150 | 5,704 |
| 2010-06-01 | 1.5 | 3 | 2 | 17,940 | 896.00 |
| 2010-03-01 | 3.4 | 17 | 5 | 293,552 | 33,773 |
| 2009-12-01 | 0.5 | 9 | 18 | 85,533 | 71,063 |
| 2009-09-01 | 1.0 | 1 | 1 | 4,000 | 715.00 |
| 2009-03-01 | 0.625 | 5 | 8 | 19,125 | 16,592 |
| 2008-12-01 | 2.1429 | 30 | 14 | 206,952 | 16,609 |
| 2008-09-01 | 23.0 | 23 | 1 | 212,982 | 0.00 |
| 2008-06-01 | 2.75 | 11 | 4 | 89,445 | 2,580 |
| 2008-03-01 | 0.4 | 2 | 5 | 16,500 | 4,326 |
| 2007-12-01 | 1.4 | 14 | 10 | 108,000 | 37,592 |
| 2007-09-01 | 0.0702 | 4 | 57 | 63,433 | 79,375 |
| 2007-03-01 | 0.3333 | 1 | 3 | 2,000 | 1,928 |
| 2006-12-01 | 2.8333 | 17 | 6 | 110,830 | 43,116 |
| 2006-09-01 | 0.0244 | 1 | 41 | 30,000 | 57,612 |
| 2006-06-01 | 0.3333 | 1 | 3 | 5,000 | 11,000 |
| 2006-03-01 | 2.0 | 10 | 5 | 90,000 | 21,446 |
| 2005-12-01 | 5.0 | 5 | 1 | 25,000 | 625.00 |
| 2005-09-01 | 1.3333 | 8 | 6 | 212,000 | 100,000 |
| 2005-06-01 | 0.125 | 1 | 8 | 3,600 | 43,600 |
| 2005-03-01 | 3.0 | 9 | 3 | 281,000 | 22,500 |
| 2004-06-01 | 1.75 | 7 | 4 | 41,000 | 2,800 |
| 2004-03-01 | 6.0 | 6 | 1 | 55,000 | 5,000 |
| 2003-12-01 | 1.0 | 10 | 10 | 78,000 | 63,000 |
SurModics Notable Stakeholders
A SurModics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as SurModics often face trade-offs trying to please all of them. SurModics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting SurModics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Gary Maharaj | CEO and President and Director | Profile | |
| Gregg Sutton | Vice President - Research & Development | Profile | |
| Charles Olson | Sr. VP and General Manager of Medical Device | Profile | |
| Joel Suiter | Director Development | Profile | |
| Timothy Arens | VP of Corporate Devel. and Strategy | Profile | |
| Joseph Stich | VP and General Manager of In-Vitro Diagnostics | Profile | |
| Gordon JD | General Legal | Profile | |
| Gordon Weber | General Legal | Profile | |
| Teryl Sides | Senior Interventions | Profile | |
| John Manders | Corporate Controller and Principal Accounting Officer | Profile |
About SurModics Management Performance
The success or failure of an entity such as SurModics often depends on how effective the management is. SurModics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of SurModics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the SurModics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.12) | (0.11) | |
| Return On Capital Employed | (0.04) | (0.04) | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (0.10) | (0.11) |
Please note, the imprecision that can be found in SurModics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of SurModics. Check SurModics' Beneish M Score to see the likelihood of SurModics' management manipulating its earnings.
SurModics Workforce Analysis
Traditionally, organizations such as SurModics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare SurModics within its industry.SurModics Manpower Efficiency
Return on SurModics Manpower
| Revenue Per Employee | 12.6M | |
| Revenue Per Executive | 12.6M | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 1.2M | |
| Working Capital Per Employee | 6.1M | |
| Working Capital Per Executive | 6.1M |
Additional Tools for SurModics Stock Analysis
When running SurModics' price analysis, check to measure SurModics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SurModics is operating at the current time. Most of SurModics' value examination focuses on studying past and present price action to predict the probability of SurModics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SurModics' price. Additionally, you may evaluate how the addition of SurModics to your portfolios can decrease your overall portfolio volatility.